Andrew Forrest-backed biotech in peanut allergy breakthrough
Aravax says clinical trials show there is hope for a more permanent solution to lethal peanut allergies in children.
Reported by The Australian Financial Review. We will add other newspapers as they cover it.
How the newspaper covers this story
Andrew Forrest-backed biotech in peanut allergy breakthrough
Aravax says clinical trials show there is hope for a more permanent solution to lethal peanut allergies in children.
